SCHEMBL5537597

SCHEMBL5537597

COc1ccccc1/C=C/CO[C]=O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NFE2L2 Q16236 4/20 0.51
TFEB P19484 1/20 0.50
KDM4E B2RXH2 4/20 0.49
TRPA1 O75762 1/20 0.49
ALDH1A1 P00352 1/20 0.47
TSHR P16473 1/20 0.47
NPC1 O15118 2/20 0.45
MAPT P10636 2/20 0.45
RAB9A P51151 2/20 0.45
LMNA P02545 1/20 0.45
BCHE P06276 1/20 0.45
CYP1A1 P04798 2/20 0.45
CYP1A2 P05177 2/20 0.45
CYP1B1 Q16678 2/20 0.45
GRIK1 P39086 1/20 0.45
GRIK2 Q13002 1/20 0.45
GRIK3 Q13003 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
MAPK1 P28482 1/20 0.44
ATM Q13315 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5537600 1.00 NFE2L2 (0.51) NFE2L2TFEBKDM4ETRPA1ALDH1A1
SCHEMBL5540192 0.86 NFE2L2 (0.55) NFE2L2KDM4EMAPTCYP1A1CYP1A2
SCHEMBL5540197 0.86 NFE2L2 (0.55) NFE2L2KDM4EMAPTCYP1A1CYP1A2
SCHEMBL5537244 0.82 ABCG2 (0.45) NFE2L2MAPTCYP1A1CYP1A2CYP1B1
SCHEMBL5537246 0.82 ABCG2 (0.45) NFE2L2MAPTCYP1A1CYP1A2CYP1B1
SCHEMBL28990287 0.81 NFE2L2 (0.56) NFE2L2TFEBKDM4ETRPA1ALDH1A1
SCHEMBL5541934 0.80 CYP1A2 (0.60) NFE2L2KDM4EALDH1A1TSHRMAPT
SCHEMBL5541931 0.80 CYP1A2 (0.60) NFE2L2KDM4EALDH1A1TSHRMAPT
SCHEMBL5542259 0.80 CYP1A1 (0.54) NFE2L2KDM4EMAPTLMNACYP1A1
SCHEMBL5542717 0.80 PTGES2 (0.41) NFE2L2TFEBALDH1A1BCHESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 NFE2L2 846/4885TFEB 3618/4885KDM4E 4854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.